NCT01551004View on ClinicalTrials.gov

Phase I Trial of a Single Dose of CRS3123

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 22, 2012

Primary Completion Date

April 7, 2014

Study Completion Date

April 21, 2014

Conditions
Clostridium Difficile Colitis
Interventions
DRUG

CRS3123

CRS3123, a methionyl-tRNA synthetase inhibitor, will be supplied in 100 and 200 milligram capsules. Subjects randomized to active drug in Cohorts A through E will receive 100 mg, 200 mg, 400 mg, 800 mg and 1200 mg respectively, as a single oral dose.

OTHER

Placebo

Matching placebo capsules will be given to 2 subjects of each cohort.

Trial Locations (1)

21224-2735

Johns Hopkins Bayview Medical Center - Infectious Diseases, Baltimore

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01551004 - Phase I Trial of a Single Dose of CRS3123 | Biotech Hunter | Biotech Hunter